Literature DB >> 24585459

VEGF-C mediates RhoGDI2-induced gastric cancer cell metastasis and cisplatin resistance.

Hee Jun Cho, In-Kyu Kim, Sun-Mi Park, Kyoung Eun Baek, In-Koo Nam, Seung-Ho Park, Ki-Jun Ryu, Jungil Choi, Jinhyun Ryu, Soon-Chan Hong, Sang-Ho Jeong, Young-Joon Lee, Gyung-Hyuck Ko, Jae Kim, Chang Won Lee, Sang Soo Kang, Jiyun Yoo.   

Abstract

Rho GDP dissociation inhibitor 2 (RhoGDI2) expression is correlated with tumor growth, metastasis and chemoresistance in gastric cancer. However, the mechanisms by which RhoGDI2 promotes tumor cell survival and metastasis remain unclear. In this study, we clearly demonstrate that RhoGDI2 upregulates VEGF-C expression and RhoGDI2 expression is positively correlated with VEGF-C expression in human gastric tumor tissues as well as parental gastric cancer cell lines. VEGF-C depletion suppressed RhoGDI2-induced gastric cancer metastasis and sensitized RhoGDI2-overexpressing cells to cisplatin-induced apoptosis in vitro and in vivo. Secreted VEGF-C enhanced gastric cancer cell invasion and conferred cisplatin resistance to RhoGDI2-overexpressing cells. We also show that RhoGDI2 positively regulates Rac1 activity in gastric cancer cells. Inhibition of Rac1 expression suppressed RhoGDI2-induced VEGF-C expression, and this inhibition was associated with decreased invasiveness and increased sensitivity to cisplatin in RhoGDI2-overexpressing cells. Our results indicate that RhoGDI2 might be a potential therapeutic target for simultaneously reducing metastasis risk and enhancing chemotherapy efficacy in gastric cancer.
© 2014 UICC.

Entities:  

Keywords:  RhoGDI2; VEGF-C; chemoresistance; gastric cancer; metastasis

Mesh:

Substances:

Year:  2014        PMID: 24585459     DOI: 10.1002/ijc.28801

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  26 in total

Review 1.  Disrupting P-glycoprotein function in clinical settings: what can we learn from the fundamental aspects of this transporter?

Authors:  Francisco S Chung; Jayson S Santiago; Miguel Francisco M De Jesus; Camille V Trinidad; Melvin Floyd E See
Journal:  Am J Cancer Res       Date:  2016-08-01       Impact factor: 6.166

2.  Regorafenib in Combination with First-Line Chemotherapy for Metastatic Esophagogastric Cancer.

Authors:  Ryan H Moy; Gustavo Dos Santos Fernandes; Philip Jonsson; Joanne F Chou; Azfar Basunia; Geoffrey Y Ku; Sree B Chalasani; Michelle S Boyar; Zoe Goldberg; Avni M Desai; Amelia Gabler; Michael F Berger; Laura H Tang; Jaclyn F Hechtman; David P Kelsen; Mark Schattner; David H Ilson; David B Solit; Barry S Taylor; Nikolaus Schultz; Marinela Capanu; Yelena Y Janjigian
Journal:  Oncologist       Date:  2019-09-30

3.  Rho GDP dissociation inhibitor-β in renal cell carcinoma.

Authors:  Christoph-Alexander von Klot; Natalia Dubrowinskaja; Inga Peters; Jörg Hennenlotter; Axel S Merseburger; Arnulf Stenzl; Markus A Kuczyk; Jürgen Serth
Journal:  Oncol Lett       Date:  2017-10-20       Impact factor: 2.967

Review 4.  The non-canonical role of vascular endothelial growth factor-C axis in cancer progression.

Authors:  Chu-An Wang; Shaw-Jenq Tsai
Journal:  Exp Biol Med (Maywood)       Date:  2015-04-16

5.  RhoGDI2 induced malignant phenotypes of pancreatic cancer cells via regulating Snail expression.

Authors:  Bin Yi; You Hu; Dongming Zhu; Jun Yao; Jian Zhou; Yi Zhang; Zhilong He; Lifeng Zhang; Zixiang Zhang; Jian Yang; Yuchen Tang; Yujie Huang; Dechun Li; Qiuhua Liu
Journal:  Genes Genomics       Date:  2022-02-11       Impact factor: 1.839

6.  Exosomes Serve as Nanoparticles to Deliver Anti-miR-214 to Reverse Chemoresistance to Cisplatin in Gastric Cancer.

Authors:  Xinyi Wang; Haiyang Zhang; Ming Bai; Tao Ning; Shaohua Ge; Ting Deng; Rui Liu; Le Zhang; Guoguang Ying; Yi Ba
Journal:  Mol Ther       Date:  2018-01-08       Impact factor: 11.454

7.  RhoGDI2 up-regulates P-glycoprotein expression via Rac1 in gastric cancer cells.

Authors:  Zhong Zheng; Bingya Liu; Xiaohua Wu
Journal:  Cancer Cell Int       Date:  2015-04-15       Impact factor: 5.722

8.  miR-101 suppresses vascular endothelial growth factor C that inhibits migration and invasion and enhances cisplatin chemosensitivity of bladder cancer cells.

Authors:  Ye Lei; Bin Li; Shiyu Tong; Lin Qi; Xiheng Hu; Yunbo Cui; Zengbo Li; Wei He; Xiongbing Zu; Zhi Wang; Minfeng Chen
Journal:  PLoS One       Date:  2015-02-06       Impact factor: 3.240

9.  Novel peptides suppress VEGFR-3 activity and antagonize VEGFR-3-mediated oncogenic effects.

Authors:  Yi-Wen Chang; Chih-Ming Su; Yen-Hao Su; Yuan-Soon Ho; Hui-Huang Lai; Hsin-An Chen; Min-Liang Kuo; Wen-Chun Hung; Ya-Wen Chen; Chih-Hsiung Wu; Pai-Sheng Chen; Jen-Liang Su
Journal:  Oncotarget       Date:  2014-06-15

10.  Screening and identification of five serum proteins as novel potential biomarkers for cured pulmonary tuberculosis.

Authors:  Chong Wang; Li-Liang Wei; Li-Ying Shi; Zhi-Fen Pan; Xiao-Mei Yu; Tian-Yu Li; Chang-Ming Liu; Ze-Peng Ping; Ting-Ting Jiang; Zhong-Liang Chen; Lian-Gen Mao; Zhong-Jie Li; Ji-Cheng Li
Journal:  Sci Rep       Date:  2015-10-26       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.